Turgeon RD, Koshman SL, Youngson E, et al. - This study was undertaken t correlate the risk of MACE with ticagrelor vs clopidogrel in patients with the acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI), to compare major bleeding and dyspnea, and to evaluate the association between P2Y12 inhibitor adherence and major adverse coronary events (MACE). Between April 1, 2012, and March 31, 2016, researchers designed a population-based cohort study utilizing data of patients discharged alive after PCI for ACS from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease registry. Primary endpoints were major adverse coronary events, a composite of all-cause death, hospitalization for ACS, unplanned coronary revascularization, or stent thrombosis within 365 days after index PCI. The hospitalization for major bleeding and emergency department visits for dyspnea were considered secondary endpoints. The outpatient use of ticagrelor was not correlated with a statistically significant decrease in MACE vs clopidogrel; nevertheless, it was correlated with more major bleeding and dyspnea, in this population-based cohort study of individuals with ACS who underwent PCI.